Oppenheimer Trims ORIC Pharmaceuticals (NASDAQ:ORIC) Target Price to $15.00

ORIC Pharmaceuticals (NASDAQ:ORIC) had its target price reduced by Oppenheimer from $17.00 to $15.00 in a report published on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.

Several other research firms also recently weighed in on ORIC. Cantor Fitzgerald reissued an overweight rating on shares of ORIC Pharmaceuticals in a research report on Thursday, June 20th. Wedbush reissued an outperform rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Monday. Citigroup dropped their target price on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a buy rating for the company in a research report on Tuesday, May 7th. Finally, HC Wainwright reissued a buy rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Wednesday, July 17th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and an average target price of $19.17.

ORIC Pharmaceuticals Stock Down 2.8 %

Shares of ORIC traded down $0.30 during midday trading on Tuesday, hitting $10.53. The company had a trading volume of 56,988 shares, compared to its average volume of 544,121. The company’s 50 day moving average price is $8.95 and its 200 day moving average price is $10.35. The stock has a market cap of $709.93 million, a price-to-earnings ratio of -5.95 and a beta of 1.13. ORIC Pharmaceuticals has a 52 week low of $5.27 and a 52 week high of $16.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its stake in ORIC Pharmaceuticals by 140.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock valued at $21,543,000 after purchasing an additional 915,175 shares during the period. Strs Ohio acquired a new position in ORIC Pharmaceuticals during the 4th quarter valued at about $72,000. AJOVista LLC acquired a new position in ORIC Pharmaceuticals during the 4th quarter valued at about $40,000. Vanguard Group Inc. boosted its stake in ORIC Pharmaceuticals by 27.9% during the 1st quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock valued at $39,628,000 after purchasing an additional 629,536 shares during the period. Finally, ProShare Advisors LLC acquired a new position in ORIC Pharmaceuticals during the 1st quarter valued at about $161,000. 95.05% of the stock is owned by institutional investors and hedge funds.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.